Literature DB >> 3132278

Cooperative study on the value of long term anticoagulation in patients with stroke and non-rheumatic atrial fibrillation.

J Lodder1, M S Dennis, L Van Raak, L N Jones, C P Warlow.   

Abstract

The benefits of long term anticoagulant treatment of patients with non-rheumatic atrial fibrillation and cerebral infarction were studied by comparing two series of patients with stroke from centres with different policies on anticoagulant treatment. The long term prognosis of 50 patients from the Oxfordshire community stroke project, who did not receive anticoagulants, was compared with that of 70 similar patients from Maastricht, who were treated with anticoagulants. After a mean follow up of 27 months there was no significant difference in either the rate of survival or the rate of recurrent stroke between the two groups. These data suggest that any benefit of anticoagulation is modest. A large randomised trial is planned to establish whether long term anticoagulant treatment is of value and, if so, to what extent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132278      PMCID: PMC2545893          DOI: 10.1136/bmj.296.6634.1435

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  13 in total

1.  The secondary prevention of stroke in patients with atrial fibrillation.

Authors:  I Starkey; C Warlow
Journal:  Arch Neurol       Date:  1986-01

2.  Beta blockade during and after myocardial infarction: an overview of the randomized trials.

Authors:  S Yusuf; R Peto; J Lewis; R Collins; P Sleight
Journal:  Prog Cardiovasc Dis       Date:  1985 Mar-Apr       Impact factor: 8.194

3.  Mechanisms of acute carotid stroke.

Authors:  M S Pessin; R C Hinton; K R Davis; G W Duncan; G H Roberson; R H Ackerman; J P Mohr
Journal:  Ann Neurol       Date:  1979-09       Impact factor: 10.422

4.  Hemorrhage and anticoagulation after nonseptic embolic brain infarction.

Authors:  A J Furlan; S J Cavalier; R E Hobbs; M A Weinstein; M T Modic
Journal:  Neurology       Date:  1982-03       Impact factor: 9.910

5.  Recurrent embolic cerebral infarction and anticoagulation.

Authors:  R L Koller
Journal:  Neurology       Date:  1982-03       Impact factor: 9.910

6.  Evaluation of the risk of immediate anticoagulant treatment in patients with embolic stroke of cardiac origin.

Authors:  J Lodder; P J van der Lugt
Journal:  Stroke       Date:  1983 Jan-Feb       Impact factor: 7.914

7.  Nonseptic cerebral emboli of cardiac origin.

Authors:  G J Martin; J Biller
Journal:  Arch Intern Med       Date:  1984-10

8.  Risk of recurrent stroke in patients with atrial fibrillation and non-valvular heart disease.

Authors:  J I Sage; R L Van Uitert
Journal:  Stroke       Date:  1983 Jul-Aug       Impact factor: 7.914

9.  Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?

Authors:  P Sandercock; C Warlow; J Bamford; R Peto; I Starkey
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  5 in total

Review 1.  Anticoagulant drugs in the elderly: the risks usually outweight the benefits.

Authors:  P J Scott
Journal:  BMJ       Date:  1988-11-12

Review 2.  Anticoagulant drugs in the elderly: valuable in selected patients.

Authors:  G D Lowe
Journal:  BMJ       Date:  1988-11-12

Review 3.  Long-term anticoagulation. Indications and management.

Authors:  B M Stults; W H Dere; T H Caine
Journal:  West J Med       Date:  1989-10

4.  How often is non-valvular atrial fibrillation the cause of brain infarction?

Authors:  G van Merwijk; J Lodder; J Bamford; A D Kester
Journal:  J Neurol       Date:  1990-06       Impact factor: 4.849

Review 5.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.